Alnylam announces 2023 product and pipeline goals and provides program updates at r&d day

Cambridge, mass.--( business wire )--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, is hosting a virtual r&d day today. during the event, the company plans to showcase its r&d progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four rnai therapeutic products, and advancement of early-, mid-, and late-stage investigational programs.
ALNY Ratings Summary
ALNY Quant Ranking